 |
2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
2022 News Releases
Dec. 7, 2022 - Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium
Read
Dec. 5, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Nov. 3, 2022 - Puma Biotechnology Reports Third Quarter 2022 Financial Results
- Raises FY 2022 NERLYNX Net Product Revenue Guidance
Read
Nov. 2, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Oct. 27, 2022 - Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
Read
Oct. 20, 2022 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read
Oct. 4, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Sept. 20, 2022 - Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
Read
Sept. 11, 2022 - Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
Read
Sept. 6, 2022 - Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Read
Sept. 2, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Aug. 5, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Aug. 4, 2022 - Puma Biotechnology Reports Second Quarter 2022 Financial Results
Read
July 21, 2022 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read
July 6, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
June 7, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
June 6, 2022 - Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Read
June 4, 2022 - Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual Meeting
Read
May 26, 2022 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting
Read
May 11, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
May 5, 2022 - Puma Biotechnology Reports First Quarter 2022 Financial Results
Read
April 27, 2022 - Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting
Read
April 21, 2022 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read
April 5, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
March 10, 2022 - Puma Biotechnology Announces $10 Million Private Placement
Read
March 7, 2022 - Puma Biotechnology to Participate in Breast Cancer Panel at Cowen’s Annual Health Care Conference
Read
March 4, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
March 3, 2022 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Read
February 16, 2022 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results
Read
February 3, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
January 20, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
January 12, 2022 - Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer
Read
January 10, 2022 - Puma Biotechnology Releases Updated Corporate Presentation
Read
January 4, 2022 - Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference
Read
2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
|
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
|
